Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28605102 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL9448994 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL9449020 | 0.79 | ALDH1A1 (0.67) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL9449036 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL9448908 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL9448906 | 0.79 | TSHR (0.52) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL82420 | 0.78 | ALDH1A1 (0.60) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL30345150 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL8715637 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL8869550 | 0.76 | ALDH1A1 (1.00) | ALDH1A1MEN1HTTKMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3976621-A | ALPHA-DIAZOACETOPHENONES, LEWIS ACID CATALYST | SNAM PROGETTI S.P.A. (IT) | 1976-08-24 | — | — | US | claimed |
| CN-118184558-A | Thiophenylamide compound, and preparation method and application thereof | 五邑大学 | 2024-06-14 | — | — | CN | disclosed |
| US-11840504-B2 | Method for preparing perfluoroalkyl sulfinate ester | SOOCHOW UNIVERSITY (CN) | 2023-12-12 | — | — | US | disclosed |
| CN-113248458-B | Preparation method of alpha-carbonyl amide compound | 陕西省煤田地质集团有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-113248458-A | Preparation method of alpha-carbonyl amide compound | 陕西省煤田地质集团有限公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-1905774-B1 | Fused heterocyclic compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | disclosed |
| US-7579470-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
| EP-0466730-B1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS | THE UPJOHN COMPANY (US) | 1993-07-21 | — | — | EP | disclosed |
| US-5220021-A | Geminal bisphosphonic acids and derivatives as anti-arthritic agents | THE UPJOHN COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0466730-A1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS. | UPJOHN CO (US) | 1992-01-22 | — | — | EP | disclosed |
| WO-1990012017-A1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS | THE UPJOHN COMPANY (US) | 1990-10-18 | — | — | WO | disclosed |
| US-4609495-A | BETA-LACTAMASE INHIBITORS, ANTIBIOTICS | BEECHAM GROUP P.L.C. (GB) | 1986-09-02 | — | — | US | disclosed |
| US-4548815-A | SYNERGISTIC MIXTURE OF AN OXAPENICILLIN AND A PENICILLIN | BEECHAM GROUP P.L.C. (GB) | 1985-10-22 | — | — | US | disclosed |
| US-4228174-A | ANTIBIOTICS | BEECHAM GROUP LIMITED (GB) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | ALDH1A1 2953/4885MEN1 1063/4885HTT 122/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | ALDH1A1 2953/4885MEN1 1063/4885HTT 122/4885 |
| US-11840504-B2 | Method for preparing perfluoroalkyl sulfinate ester | TERT, TST, CTH | ALDH1A1 210/4885MEN1 4812/4885HTT 1423/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | ALDH1A1 2953/4885MEN1 1063/4885HTT 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.